Sunshine Registers 31.1M Series B Warrant Shares at $2.7674 Strike
SBFM is trading near its 52-week low of $2.41 (0.0% above the low) on light trading volume (0.1× avg).
Summary
Sunshine Biopharma filed an S-1 to register 31,087,198 shares issuable on exercise of its Series B Warrants, currently struck at $2.7674. No shares were sold; full cash exercise would raise about $31 million, but the warrants carry a ratchet that lowers the strike if stock is sold below it.
Key Events · Financing and Capital Events · SBFM
-
S-1 Registers 31.1M Warrant Shares
The registration covers 31,087,198 shares issuable on exercise of Series B Warrants, estimated on an assumed adjusted exercise price of $1.00; 11,233,359 Series B Warrants are currently outstanding.
-
Cash Exercise Would Raise ~$31M
At the current $2.7674 exercise price, full cash exercise would produce gross proceeds of about $31 million (31,087,198 x $1.00 = $31,087,198 per the fee table; the prospectus states approximately $31 million net). The filing states there is no assurance any warrants will be exercised.
-
Warrant Ratchet Can Lower Strike
If Sunshine issues or agrees to sell stock below the then-current exercise price, that price resets to the lower figure and the share count is adjusted upward so aggregate exercise proceeds stay unchanged — a discounted raise would enlarge the overhang.
-
Nasdaq Listing Pressure Disclosed
The company says it does not currently meet the proposed $5 million Market Value of Listed Securities requirement and remains subject to immediate delisting notice on any 30-day bid price shortfall until October 2027, following the 1-for-20 reverse split effective October 26, 2026.
Analysis · SBFM · Life Sciences
This is a registration statement, not a sale: no shares have been issued and no cash has been received. Its purpose is to put a resale/exercise shelf in place so the 11,233,359 outstanding Series B Warrants can only be exercised for cash rather than through the cashless formula. Were every warrant exercised at the current $2.7674 strike, gross proceeds would be about $31 million — roughly double the $14.6 million cash the company reported at September 30 — though the filing itself says there is no assurance any warrants will be exercised. The real risk sits in the ratchet: if Sunshine sells stock below the then-current exercise price, that price resets lower and the share count rises proportionately, so a future discounted raise could expand this overhang well beyond the 31.1 million shares registered here. With the stock trading at $2.41, near its 52-week low, and the company already failing the proposed $5 million market value listing test, the practical read is more potential supply overhanging a thinly valued equity.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SBFM was trading at $2.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2M. The 52-week trading range was $2.41 to $464.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.